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Abstract
Two CF patients developed Cushing’s syndrome during administration of inhaled budesonide (400 mgyd) with oral itraconazole
in one and with clarithromycin in the other patient. Clinical features appeared respectively after 2 and 6 weeks of drug co-
administration, with prolonged adrenal suppression, and a slow recovery after ceasing the drugs. Inhibitors of the cytochrome
P450 interfere with the metabolism of corticosteroids. Combination of these drugs even with moderate doses of budesonide should
be closely monitored.
 2003 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Iatrogenic Cushing’s syndrome has been reported
previously in children using intranasal, inhaled and skin
applied steroids w1–5x. Steroids had been mostly given
for a prolonged time, or were intermittently associated
with oral steroids. The most common use of inhaled
corticosteroids is for the maintenance anti-inflammatory
treatment of asthma. This route of administration is also
of benefit to reduce the use of systemic steroids in
allergic bronchopulmonary aspergillosis (ABPA), seen
in about 10% of cystic fibrosis patients (CF) w6x.
CF patients have a higher distribution volume and a
higher clearance rate for glucocorticoids as well as an
enhanced biotransformation w7x. Higher doses of corti-
costeroids are required to obtain the same results as in
non-CF patients. An iatrogenic Cushing’s syndrome is
therefore less likely to be suspected, especially with
moderate doses of inhaled steroids. Furthermore, the
frequent use of multiple medications such as azole-
derivates (ketoconazole, itraconazole«), macrolides and
cisapride, can put them at particular risk for iatrogenic
hypercorticism and pharmacological interaction in gen-
eral. The drugs mentioned above are metabolised by
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cytochrome P450 (CYP3A4), mostly present in the liver,
and thereby inhibit metabolism of exogenous cortico-
steroids, since the latter are also partially metabolised
by CYP3A4, and act as inhibitors w8–10x. Recently the
prolonged use of itraconazole and inhaled steroids in
CF-patients with ABPA was reported to induce adrenal
suppression w8–10x. Interaction of clarithromycin thera-
py and methylprednisolone elimination has been report-
ed, but not in association with inhaled steroids w11x.
We found Cushing’s syndrome during inhalation of
moderate doses of budesonide in 2 CF patients. A young
boy developed Cushing’s syndrome after only 2 weeks
of concomitant treatment with itraconazole and a female
adult presented a Cushing on long-term clarithromycin
therapy for Mycobacterium abscessus infection 6 weeks
after addition of inhaled budesonide.
2. Case reports
Case 1: CF was diagnosed (DF508yG542X) at birth,
because of a meconeumileus. After ileal resection, clin-
ical evolution was satisfactory, with weight and height
being on percentile P75 and P50 respectively. He
received aerosols with salbutamol (Ventolin ), r-DNAse
(Pulmozyme ) and mesna (Mistabron ), pancreatic 
enzymes (Pancrease ) and fluticasonpropionate nose
spray (Flixonase-aqua 50 mg 2=yd). His pulmonary
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infections were moderate and treated with oral antibiot-
ics. At the age of 4 years, he was admitted for pulmonary
deterioration with severe bronchorrea and wheezing.
FEV1 decreased from a perfect value of 127 to 90%,
chest X-ray was normal and bronchoaveolar lavage
(BAL) cultures were positive for Escherichia coli with
an extended spectrum of beta-lactamase. Because of
persistent bronchospasm, inhaled steroids (budesonide
Miflonide 2=200 mgyd) and long acting b2-mimetics
(formoterolfumarate Foradil 1=12 mgyd) were started.
Antibiotics (ciprofloxacine and meropenem) and 2=100
mgyd of the oral itraconazole formula (Sporanox )
were also added. ABPA was suspected, because of a
strongly positive skin test for Aspergillus fumigatus, IgE
elevation for Aspergillus (class 2) and a slight elevation
of total IgE (120 kIUyl). Two weeks after starting
budesonide, the child developed a moon face, a swollen
abdomen and had a weight gain of 1.5 kg. Blood
pressure was moderately elevated to 111y75 mmHg.
AST, ALT and glycemia were normal. A morning blood
sample demonstrated a free cortisol of -3 mgyl,
immeasurable levels of ACTH, DHEA-S and a very low
24-h urinary free cortisol excretion, compatible with a
complete suppression of the hypothalamic–pituitary–
adrenal axis (HPA-axis). Respiratory signs improved
progressively. Itraconazole was stopped immediately and
the dose of budesonide was reduced and stopped later.
The fluticasonpropionate nose spray was continued. To
prevent an acute Addison’s crisis, hydrocortisone was
started at a normal physiological dose of 20 mgym .2
Blood pressure normalised, but the moon face persisted.
Four months after ceasing budesonide, serum cortisol
was rising to 34 mgyl, remaining still too low, indicating
prolonged adrenal suppression, although clinical signs
of a Cushing’s syndrome had disappeared.
Case 2 was a non-diabetic pancreatic-sufficient
mother of two children with mild lung disease (FEV1:
86%) diagnosed as CF at the age of 30 years (3272-
26A to GyDF508).
Since diagnosis, Mycobacterium abscessus was the
only pathogen ever isolated. Therefore, she was treated
continuously with inhaled amikacin and in periods of 3
months intravenously. On account of respiratory decline,
clarithromycin (500 mg bid) was added for 4 years.
Smear positivity never ceased. After a sudden FEV1
decline from 58 to 30%, inhaled budesonide (2=200
mgyd) and salmeterol (2=50 mgyd) were started togeth-
er with oxygen supplements. Six weeks later, she devel-
oped a moon face, a weight gain of 5 kg and a rise in
blood pressure to 140y95 mmHg. Morning serum free
cortisol, ACTH, DHEA-S were immeasurable, indicating
again complete suppression of the HPA-axis and oral
hydrocortisone supplement was started. A slow rise in
morning free cortisol was seen 4 weeks after ceasing
budesonide. Unfortunately, she died 8 weeks later of
severe respiratory failure with high inflammatory para-
meters (CRP)500 mgyl), 10 years after CF diagnosis.
3. Discussion
Both patients were suffering from a pulmonary infec-
tion with an unusual pathogen, respectively, Escherichia
coli with an extended spectrum of beta-lactamase and
Mycobacterium abscessus, for which specific antimicro-
bial medication is needed.
Moreover, ABPA was suspected in the first case.
Having two clinical and one immunological criteria
prompted us to start treatment with itraconazole and
budesonide, although diagnosis remained doubtful.
ABPA diagnosis is difficult in CF, especially in very
young children, because several of the ABPA diagnostic
criteria overlap with common CF manifestations w6,12x.
Since the availability of itraconazole, the doses of
systemic steroids can be reduced and in some cases
replaced by inhaled steroids. The second patient showed
rapid fatal pulmonary decline, as described in CF with
Mycobacterium abscessus infection, despite aggressive
treatment with first choice antibiotic being clarithromy-
cin w13x. Rapid weight gain, facial changes and arterial
hypertension were the clinical signs of a Cushing’s
syndrome. Complete suppression of the HPA-axis was
evident in both cases from the immeasurable levels of
cortisol, ACTH, DHEA-S and very low 24-h urinary
free cortisol excretion. The temporal relationship and
the slow recovery after stopping medication, as reported,
are very suggestive for a causative correlation.
Azole-derivates (ketoconazole, itraconazole«) and
macrolides are inhibitors of CYP3A4 and can inhibit
the metabolism of corticosteroids. Previous publications
already noted an interaction, but after a prolonged
treatment, between azole-derivates and systemic corti-
costeroids and even in some cases with high doses of
inhaled steroids w8–10x (more than 6 years of co-
administration) w9x, resulting in an increased concentra-
tion of systemic budesonide. It is important to mention
that different types of corticosteroids have a different
sensitivity to CYP-inhibitors (stronger effect on methyl-
prednisolone, compared to prednisone) w8x. Neverthe-
less, the two most at present used inhaled corticosteroids
(budesonide and fluticasone) are both strong CYP3A4-
dependent w9,14x. Our patients only used moderate daily
doses of inhaled steroids for 2–6 weeks, suggesting that
the interaction is neither treatment duration nor treatment
dose-related. Interaction between clarithromycin and oral
methylprednisolone is described, but not in association
with inhaled steroids w11x. We do not believe in an
insidious adrenal suppression due to chronic treatment
with fluticasone nose spray in the first patient, because
of the stable and normal blood pressure values during
clinical follow up under nasal fluticasone. Moreover, the
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estimated bioavailability of intranasal fluticasone is less
than 1% w1x.
CYP3A4 is not only present in the liver, but also in
the gut and therefore responsible for a low oral bioa-
vailability. In the presence of CYP3A4-inhibitors, the
ingested part of the aerosolised budesonide will not be
metabolised presystemically and therefore will enter the
systemic circulation. The inhaled part of budesonide
will be cleared at a lower rate in the presence of these
CYP3A4-inhibitors, and will also contribute to a higher
systemic effect w1,4x. Hypothetically, we can speculate
that the systemic absorption of inhaled steroids could
be higher in a situation of hypervascularity due to local
inflammation, possibly induced by E. coli together with
ABPA or Mycobacterium abscessus infection, even at
moderate doses of inhaled steroids, as in our two cases.
It is difficult to estimate which part of budesonide is
swallowed, since in the 1st patient an aerolizer is used.
To our knowledge there are no large data about the
ingested portion in young children. In the 2nd patient
an MDI spacer was used.
Moreover, azole-derivates play a dual role in the
development of adrenal suppression, indirectly by raising
exogenous systemic levels of corticoids and directly by
inhibiting cortisol synthesis. Inhibition of cortisol syn-
thesis at the level of the 17- to 20-desmolase, 16a-,
17a-, 18-hydroxylase and 11b-hydroxylase is mainly
reported with ketoconazole, but also with fluconazole,
itraconazole and other azole-derivates w8,9x. However,
in a recent study of CF patients with ABPA, no sup-
pression of adrenal function could be found when
itraconazole monotherapy was given, suggesting the
CYP450 interaction to be the major mechanism w9x. The
same effect of clarithromycin on cortisol synthesis might
be suspected, but is less documented w9,11x.
To our knowledge, these are the first reports of a very
abrupt development of a Cushing’s syndrome shortly
after combining treatment of moderate doses of inhaled
steroids and CYP3A4 inhibiting drugs. The first patient’s
young age could play a role, although maturation of the
cytochrome system is already completed at the age of 1
year w15,16x. In the second case the prolonged use of
clarythromycin could play a role, as well as her terminal
condition. Higher tissue glucocorticoid sensitivity can
be an underlying mechanism in the rapidly developing
side effects of the steroid therapy in our patients.
Additionally, an individual sensitivity in the cytochrome
system might play a role, as CYP3A4 is characterised
by substantial intersubject variability w17x. Eventually, a
higher systemic absorption through an inflammatory
bronchial mucosa could also be a possible hypothesis
as suggested above. None of the two described patients
had liver disease. It is unknown if CF patients with liver
disease could be more susceptible to drug interactions.
We recommend awareness for iatrogenic adrenal sup-
pression when CYP3A4 inhibiting drugs are used in
combination with inhaled and some systemic steroids,
even in low dose and short treatment plans as in these
reported cases. Combination of those types of medica-
tion should be avoided, but if impossible, blood samples
for free cortisol and ACTH should be taken to diagnose
subclinical adrenal suppression in an early stage.
Finally, medication interaction will become an
increasing problem to deal with especially in those
patients taking multiple drugs as in CF. These interac-
tions may result in an enhanced or a decreased clearance
and consequently in a diminished therapeutic response
or an increased risk for adverse events.
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